Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
NCT ID: NCT01042119
Last Updated: 2010-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2010-01-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botulin-A Toxin Instillations and Overactive Bladder
NCT00583219
Refractory Urge Incontinence and Botox Injections
NCT00373789
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
NCT02161159
Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.
NCT00231491
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
NCT05463822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Botox
patients who received intravesical injections of botulinum neurotoxin type A
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital of Zurich, Clinic for Gynaecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David A Scheiner, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Zurich, Clinic for Gynaecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Zurich, Clinic for Gynaecology
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FHKUSZ15-2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.